Effects of low-dose aspirin and heparin on the pregnancy outcome in women with antiphospholipid syndrome.

Abstract

The purpose of this study was to compare the use of low-dose aspirin alone versus prednisone and low-dose aspirin versus heparin and low-dose aspirin in the treatment of the antiphospholipid antibody syndrome in pregnant women. A prospective, single-center randomized trial included 14 patients who were alternately assigned to treatment. Each patient had a history of recurrent miscarriage diagnosed with antiphospholipid syndrome. 5 accepted the treatment of aspirin alone, 5 accepted the combination treatment of aspirin+prednisone, and 4 accepted the combination therapy of aspirin+heparin. Data were compared by the One-way ANOVA test using IBM SPSS stats 19. There were no significant differences in patient outcome data, obstetric complications, and gestational age at delivery in live births between the 3 groups (P>0.05). However, treatment with aspirin+heparin increased neonatal weight (P<0.05). Our data demonstrate the non-superiority one on each other of the three different regimens, except in terms of neonatal weight when aspirin+heparin were used. These findings raise questions about the need for therapies such as heparin and corticosteroids for women with antiphospholipid antibody syndrome, especially in resource-limited settings similar to Syria.